UniProtKB/Swiss-Prot P02671: Variant p.Arg573Leu

Fibrinogen alpha chain
Gene: FGA
Chromosomal location: 4q28
Variant information

Variant position:  573
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Arginine (R) to Leucine (L) at position 573 (R573L, p.Arg573Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In AMYL8.
Any additional useful information about the variant.



Sequence information

Variant position:  573
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  866
The length of the canonical sequence.

Location on the sequence:   IFTNTKESSSHHPGIAEFPS  R GKSSSYSKQFTSSTSYNRGD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IFTNTKESSSHHPGIAEFP--SRGKSSSYSKQFT-SSTSYNRGD

Rat                           IFTDIENPSSHVP---EFS--SSSKTSTVRKQVT-------

Bovine                        EFAALGESGS-----------SSSKTSTHSKQFVSSSTTVN

Chicken                       KFTDLGEEEEDDFGGLQPSGFAAGSASHSKTVLTSSSSSFN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 36 – 866 Fibrinogen alpha chain
Coiled coil 68 – 631
Modified residue 565 – 565 4-hydroxyproline; by P4HA1
Cross 558 – 558 Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-?)
Cross 575 – 575 Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-?)
Cross 581 – 581 Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-?)


Literature citations

Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain.
Benson M.D.; Liepnieks J.; Uemichi T.; Wheeler G.; Correa R.;
Nat. Genet. 3:252-255(1993)
Cited for: VARIANT AMYL8 LEU-573;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.